Ken Griffin Viridian Therapeutics, Inc.\De Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Citadel Advisors LLC holds 28,200 shares of VRDN stock, worth $610,248. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,200

Previous 31,300 9.9%

Holding current value

$610,248

Previous $407,000 57.49%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$12.16 - $23.33 $2.39 Million - $4.59 Million	196,596 Added 440.1%	241,267 $5.49 Million
Q2 2024 Aug 14, 2024	SELL	$11.6 - $17.26 $8.33 Million - $12.4 Million	-717,740 Reduced 94.14%	44,671 $581,000
Q1 2024 May 15, 2024	SELL	$17.09 - $23.82 $2.12 Million - $2.96 Million	-124,230 Reduced 14.01%	762,411 $13.3 Million
Q4 2023 Feb 14, 2024	BUY	$11.12 - $22.5 $8.72 Million - $17.6 Million	784,210 Added 765.6%	886,641 $19.3 Million
Q3 2023 Nov 14, 2023	BUY	$15.16 - $24.7 $251,383 - $409,575	16,582 Added 19.32%	102,431 $1.57 Million
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $85,630 - $112,567	3,794 Added 4.62%	85,849 $2.04 Million
Q1 2023 May 15, 2023	SELL	$25.04 - $37.6 $28.1 Million - $42.1 Million	-1,120,263 Reduced 93.18%	82,055 $2.09 Million
Q4 2022 Feb 14, 2023	SELL	$18.78 - $29.74 $2.97 Million - $4.71 Million	-158,294 Reduced 11.63%	1,202,318 $35.1 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $4.58 Million - $10.9 Million	428,313 Added 45.94%	1,360,612 $27.9 Million

Others Institutions Holding VRDN

# of Institutions

176

Shares Held

76.5M

Call Options Held

566K

Put Options Held

357K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $863M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account